in actie
Belgium, 7nd March 2016
To: Mr. Paul Smallcombe, Records & Information Compliance Manager (Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.)
To: Professor Simon Gaskell, Principal (Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.)
Queen Mary University of London
Mile End Road
London E1 4NS, UK
Copy to:
Dr. Richard Horton (Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.)
The Lancet
125 London Wall
London, EC2Y 5AS, UK
Dear Sirs,
Myalgic Encephalomyelitis (ME) (WHO-ICD-10 G93.3) – which is unjustly called Chronic Fatigue Syndrome (“chronisch vermoeidheidssyndroom” or in short “CVS”) in Belgium – is a chronic, complex, multi-systemic disease that devastates the lives of millions around the word, and for which there is currently no cure 1. Based on available epidemiological data, it is estimated that in Belgium between 20,000-30,000 patients are affected by this disease.
There is a growing international concern expressed both from scientists inside and outside the ME field/community 2 with respect to the methodological flaws of the PACE trial 3, which have now been clearly established.